Altimmune, Inc. (NASDAQ:ALT) Q3 2023 Earnings Call Transcript

So, the study is really meant to look forward towards the combination studies and how the patients would present themselves for treatment with HepTcell.

Louis Susser: Sounds great. Can you just remind me quickly, is this with or without interfering and do you plan to have an arm with and without interferon in that combination setting?

Scot Roberts: So the current study does not include interferon in the treatment regime. Going forward, I think that there’s any number of combination approaches that can be envisioned and that’s something that we’ll talk more about as we get a little further down the road.

Louis Susser: Sounds good. Thank you, so much.

Operator: Thank you. And as there are no further questions in the queue at this time, I will now turn the call back over to Dr. Vipin Garg for any closing remarks.

Vipin Garg: Thank you, everyone for participating today. We appreciate the opportunity to share our results and outlook with you, and thank you for your continued interest. Have a nice day.

Operator: Ladies and gentlemen, that does conclude our conference for today. Thank you for your participation. You may now disconnect.